Last checked at 26 May 2016 15:36
Eden Research Plc
("Eden" or "Company")
Director/PDMR Shareholding
Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that Robin Cridland, Non-Executive Director, today purchased 47,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 10.4 pence per share.
As a result of this transaction, Mr Cridland is interested in 47,000 Ordinary Shares in the Company, representing approximately 0.03 per cent of the issued share capital.
Eden also announces that Alex Abrey, Chief Financial Officer, was yesterday granted 1,050,000 share options to purchase Ordinary Shares at an exercise price of 13 pence with effect from the 25 May 2016 and an expiry date of 24 May 2021.
Eden Research plc | www.edenresearch.com |
Sean Smith, Chief Executive Officer | Tel: 01285 359 555 |
Alex Abrey, Chief Financial Officer |
|
|
|
Shore Capital and Corporate Limited | www.shorecap.com |
Stephane Auton/Patrick Castle | Tel: 020 7408 4090 |
|
|
Walbrook PR Ltd | Tel: 020 7933 8780 or eden@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
Notes:
Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.
Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic hydrophobic compounds. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.
Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.
With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.
The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into licence agreements.
In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represents a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.
3AEY has already been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain and Italy.
Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.
For more information about Eden, please visit: www.edenresearch.com